Device Trial Radar · NCT05374187
Efficacy of Trigeminal Nerve Stimulation for ADHD
Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
218
Actual
Start
Sep 1, 2022
Primary completion
Apr 10, 2026
Study completion Apr 10, 2026
Sponsor
- Lead sponsor
- University of California, Los AngelesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- First posted
- May 16, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 7 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a large multisite randomized clinical trial to asses the efficacy of external trigeminal nerve stimulation (TNS), a novel, minimal risk, non-invasive neuromodulation treatment, for ADHD in children ages 7-12 years old (N=180). Study hypotheses address potential differences in ADHD symptoms over 4 weeks treatment with active vs. sham TNS in an expanded multi-site investigation; whether resting state fronto-parietal connectivity mediates TNS impact on ADHD symptoms; if changes in fronto-parietal activation, as measured by electroencephalography (EEG), predict TNS-related treatment outcomes; and whether a baseline cognitive profile similarly predicts response to TNS therapy.
Conditions
- Attention-Deficit Hyperactivity Disorder
Interventions
Active eTNSDevice
Participants will receive active trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. Participants deemed to be positive responders to blinded active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
Sham eTNSDevice
Participants will receive sham trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. At conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open active eTNS treatment. Participants deemed to be positive responders to open active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in ADHD Rating Scale-5 (ADHD-RS-5)Time frame: Baseline, weeks 1, 2, 3, 4, 5, 6, 7, 8, 16, 20
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California
Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.